This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Biosimilar Rituximab (Teva)
Teva Pharmaceutical Industries Ltd.
Drug Names(s): TL011, Rituxan Biosimilar, rituximab, TL-011
Description: TL011 is a biosimilar to Roche's antibody drug Rituxan. The antibody binds to the CD20 antigen present on B cells and B cell tumors, leading to the elimination of these cells.
Teva and Lonza entered into a partnership in January 2009 to develop biosilimars, including TL011.
In July 2013, Lonza announced that following a strategic review of the Teva-Lonza joint venture (TL-JV) by the Lonza Board of Directors, the companies have agreed to discontinue their collaboration for the development, manufacturing, and marketing of biosimilars.
Biosimilar Rituximab (Teva) News
Additional information available to subscribers only: